Data Sciences: our stats team recently arranged data from a registry of 57,000+ patients to underscore the development of a risk calculator to help clinicians decide on effective and safe courses of treatment for AF patients. The tool has seen excellent adoption globally via QxMD.
How can we help you?
With our extensive experience in lab based research, new therapy development and events, TRI is glad to extend our in-house expertise to new partners.
Comms and Events: TRI has independently organised the International Society of Thrombosis congress for 20+ years, including the development of research presentations as well as logistics and communications support.